Conference Call Scheduled for 8:00 a.m. ET Today
Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the April 15th expiration.
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate
Cramer is concerned about Omega Healthcare, expects a healthy quarter for Fitbit and isn't recommending Tesoro.
Now's the time to roll up your sleeves and figure out what to buy, Cramer says. That job has been made easier by a strong earnings season.
--Conference Call Scheduled for Thursday, February 25 at 8:00 a.m. Eastern Time--
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate
Celldex will announce the outcome of an interim analysis for a pivotal study of its brain tumor therapy Rintega within weeks.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate
Biotech stocks are buried in a deep hole. To climb out, companies will have to generate some positive news.
In trading on Thursday, shares of Celldex Therapeutics, Inc. touched a new 52-week low of $9.66/share.
Cramer sees First Solar going higher and wants no part of Atwood Oceanics.
Until oil prices stabilize, don't expect any meaningful relief in the stock market, Cramer says.
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Immunotherapy is changing the way the medical community thinks about treating cancer.
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate
Here's how to trade four stocks spiking on increased trading volume.
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
